Cell-free DNA in Acute Stroke

Recruiting now

Conditions studied: Stroke

In brief

Cell-free DNA (cfDNA) is an important pro-inflammatory and prothrombotic mediator. With this study the investigators aim to gain new insights into the role of cfDNA in stroke and to perform a combined analysis of cfDNA in the hyperacute phase of the disease using blood and thrombus analyses. The main objectives are to analyse cfDNA in different stroke etiologies, to investigate the relationship between cfDNA and important procedural factors such as secondary embolisation and reperfusion outcomes, to analyse the correlation between blood and thrombus content of cfDNA and to investigate the specific source of cfDNA in distinct stroke subtypes.

Key facts

Study ID

NCT06928675

Run by

University Hospital, Basel, Switzerland

People needed

200

Starts

2025-03-30

Expected to finish

2026-09-01

Last updated by the study team

2025-04-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Acute ischemic stroke due to large vessel occlusion (LVO) who require mechanical thrombectomy (detected in CT-Scan or MRI-Scan)
• 18 years of age

You may not qualify if…

• Patients currently undergoing immunological therapies.
• Patients with immunological diseases
• Patients with systemic infections at the time of admission

Where it is running

• University Hospital Basel — Basel, Switzerland (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.